

Supplementary Table 1: Patient demographics of comparative cohort (Schrezenmeier et.al.)(1)

Table I

Characteristics of kidney transplant (KTX) patients enrolled (n=25)

Variable	
Age (mean yrs ± SD)	59.7 (13.8)
Females (%)	11 (44.0)
Caucasians (%)	25 (100)
Heterologous vaccine protocol	11
Clinical Parameters	
Time since Tx (mean yrs ± SD)	10.4 (8.69)
Retransplantation (%)	5 (20.0)
Acute graft rejection (%) ^A	0 (0)
IS medication	
CS+Tac+MMF (%)	13 (56.0)
CS+CyA+MMF (%)	7 (28.0)
mTOR _i +MMF±CS (%)	3 (12.0)
CyA+mTOR _i (%)	1 (4.0)
CS+MMF (%)	1 (4.0)
Comorbidities	
Hypertension (%)	23 (92.0)
Coronary heart disease (%)	6 (24.0)
History of myocardial infarction (%)	2 (8.0)
Diabetes (%)	5 (20.0)
History of liver disease (%)	4 (16.0)
History of malignancy (%)	6 (24.0)

CS – Corticosteroids, Tac – Tacrolimus, CyA – Cyclosporin A, MMF – Mycophenolate Mofetil, mTOR_i – mammalian target of rapamycin inhibitor. SD – standard deviation. ^A until 19–27 days after third vaccination

1. Schrezenmeier E, Rincon-Arevalo H, Stefanski AL, Potekhin A, Staub-Hohenbleicher H, Choi M, et al. B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. *J Am Soc Nephrol.* 2021.